Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis

Therapeutic Advances in Musculoskeletal Disease

Volumn 7, Issue 3, 2015, Pages 88-102

  Törring, Ove ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

antiresorptive therapy; bisphosphonate; bone density; bone mass; bone strength; cortical porosity; denosumab; Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months study; receptor activator of nuclear factor B ligand

Indexed keywords

ALENDRONIC ACID; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; TUMOR NECROSIS FACTOR ALPHA; ZOLEDRONIC ACID;

ANAPHYLAXIS; BONE DENSITY; BONE MASS; BONE REMODELING; BONE STRENGTH; CELLULITIS; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CORTICAL BONE; CORTICAL THICKNESS (BONE); DIAPHYSIS; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; ECZEMA; ERYSIPELAS; FEMUR FRACTURE; FEMUR NECK; HIP FRACTURE; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; LONG TERM CARE; LUMBAR SPINE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POROSITY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RADIUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TIBIA;

EID: 84930521037     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X15579189     Document Type: Review

References (65)

1. Anderson D. Maraskovsky E. Billingsley W. Dougall W. Tometsko M. Roux E. et al. (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175–179.
2. Austin M. Yang Y. Vittinghoff E. Adami S. Boonen S. Bauer D. et al. (2012) Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res 27: 687–693.
3. Baron R. Ferrari S. Russell R.G. (2011) Denosumab and Bisphosphonates: Different Mechanisms of Action and Effects. Bone 48: 677–692.
4. Baron R. Hesse E. (2012) Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab 97: 311–325.
5. Bekker P. Holloway D. Rasmussen A. Murphy R. Martin S. Leese P. et al. (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19: 1059–1066.
6. Bilezikian J. Benhamou C. Lin C. Brown J. Daizadeh N. Ebeling P. et al. (2014) Denosumab restores cortical bone loss at the distal radius associated with aging and reduces wrist fracture risk: analyses from the FREEDOM extension cross-over group. J Bone Miner Res 29(Suppl. 1): abstract #1047. Available at: http://www.asbmr.org/education/2014-abstracts (accessed 22 September 2014).
7. Black D. Cummings S. Karpf D. Cauley J. Thompson D. Nevitt M. et al. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348: 1535–1541.
8. Black D. Schwartz A. Ensrud K. Cauley J. Levis S. Quandt S. et al. (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial. JAMA 296: 2927–2938.
9. Black D. Delmas P. Eastell R. Reid I. Boonen S. Cauley J. et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809–1822.
10. Black D. Reid I. Boonen S. Bucci-Rechtweg C. Cauley J. Cosman F. et al. (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the Horizon-Pivotal Fracture Trial (PFT). J Bone Miner Res 27: 243–254.
11. Bolognese M. Teglbjaerg C. Zanchetta J. Lippuner K. McClung M. Brandi M. et al. (2013) Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study. J Clin Densitom 16: 147–153.
12. Bone H. Bolognese M. Yuen C. Kendler D. Miller P. Yang Y. et al. (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96: 972–980.
13. Bone H. Chapurlat R. Brandi M. Brown J. Czerwinski E. Krieg M. et al. (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98: 4483–4492.
14. Bone H. Hosking D. Devogelaer J. Tucci J. Emkey R. Tonino R. et al. (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199.
15. Boonen S. Adachi J. Man Z. Cummings S. Lippuner K. Torring O. et al. (2011) Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 96: 1727–1736.
16. Brown J. Prince R. Deal C. Recker R. Kiel D. de Gregorio L. et al. (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24: 153–161.
17. Brown J. Roux C. Torring O. Ho P. Beck Jensen J. Gilchrist N. et al. (2013) Discontinuation of denosumab and associated fracture incidence: analysis from the fracture reduction evaluation of denosumab in osteoporosis every 6 months (FREEDOM) trial. J Bone Miner Res 28: 746–752.
18. Chesnut C. Skag A. Christiansen C. Recker R. Stakkestad J. Hoiseth A. et al. (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. Journal of Bone and Mineral Research 19: 1241–1249.
19. Cummings S. San Martin J. McClung M. Siris E. Eastell R. Reid I. et al. (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361: 756–765.
20. Eastell R. Christiansen C. Grauer A. Kutilek S. Libanati C. McClung M. et al. (2011) Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 26: 530–537.
21. Ettinger B. Black D. Mitlak B. Knickerbocker R. Nickelsen T. Genant H. et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282: 637–645.
22. Ferrari S. Adachi J. Zapalowski C. Miller P. Reginster J. Törring O. et al. (2013) Further reduction in the nonvertebral fracture rate is observed following 3 years of denosumab treatment: results with up to 7 years in the FREEDOM extension. J Bone Miner Res 28(Suppl. 1): abstract #1017. Available at: http://www.asbmr.org/education/2013-abstracts (accessed 23 August 2014).
23. Geller M. Wagman R. Ho P. Siddhanti S. Stehman-Breen C. Watts N. et al. (2014) Findings from denosumab (Prolia(R)) post-marketing safety surveillance for atypical femur fracture, osteonecrosis of the jaw, severe symptomatic hypocalcemia, and anaphylaxis. J Bone Miner Res 29(Suppl. 1): abstract FR0388. Available at: http://www.asbmr.org/education/2014-abstracts (accessed 6 October 2014).
24. Genant H. Engelke K. Hanley D. Brown J. Omizo M. Bone H. et al. (2010) Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 47: 131–139.
25. Genant H. Libanati C. Engelke K. Zanchetta J. Hoiseth A. Yuen C. et al. (2013) Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab. Bone 56: 482–488.
26. Hansen S. Hauge E. Beck Jensen J. Brixen K. (2013) Differing effects of PTH 1–34, PTH 1–84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-PQCT. J Bone Miner Res 28:736–745.
27. Harris S. Watts N. Genant H. McKeever C. Hangartner T. Keller M. et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282: 1344–1352.
28. Hochberg M. Greenspan S. Wasnich R. Miller P. Thompson D. Ross P. (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87: 1586–1592.
29. Hofbauer L. Schoppet M. (2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292: 490–495.
30. Hsu H. Lacey D. Dunstan C. Solovyev I. Colombero A. Timms E. et al. (1999) Tumor necrosis factor receptor family member rank mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96: 3540–3545.
31. Jiang Y. Zhao J. Mitlak B. Wang O. Genant H. Eriksen E. (2003) Recombinant human parathyroid hormone (1–34) [Teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18: 1932–1941.
32. Keaveny T. McClung M. Genant H. Zanchetta J. Kendler D. Brown J. et al. (2014) Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. J Bone Miner Res 29: 158–165.
33. Kendler D. McClung M. Freemantle N. Lillestol M. Moffett A. Borenstein J. et al. (2011) Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 22: 1725–1735.
34. Kostenuik P. (2005) Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Current Opinion in Pharmacology 5:618–625.
35. Kostenuik P. Smith S. Jolette J. Schroeder J. Pyrah I. Ominsky M. (2011) Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone 49: 151–161.
36. Lacey D. Timms E. Tan H. Kelley M. Dunstan C. Burgess T. et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165–176.
37. Lee D. Hoffmann P. Varela A. Kostenuik P. Ominsky M. Keaveny T. (2014) Finite element analysis accurately reflects the improvements in vertebral strength with denosumab in ovariectomized cynomolgus monkeys. J Bone Miner Res 29(Suppl. 1): abstract #SA0388. Available at: http://www.asbmr.org/education/2014-abstracts (accessed 6 October 2014).
38. Lewiecki E. Miller P. McClung M. Cohen S. Bolognese M. Liu Y. et al. (2007) Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 22: 1832–1841.
39. Li J. Sarosi I. Yan X. Morony S. Capparelli C. Tan H. et al. (2000) RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97: 1566–1571.
40. Mandema J. Zheng J. Libanati C. Perez Ruixo J. (2014) Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response based meta-analysis. J Clin Endocrinol Metab 99: 3746–3755.
41. McClung M. Boonen S. Törring O. Roux C. Rizzoli R. Bone H. et al. (2012) Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res 27: 211–218.
42. McClung M. Geusens P. Miller P. Zippel H. Bensen W. Roux C. et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.N Engl J Med 344: 333–340.
43. McClung M. Lewiecki E. Cohen S. Bolognese M. Woodson G. Moffett A. et al. (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 821–831.
44. McClung M. Lewiecki E. Geller M. Bolognese M. Peacock M. Weinstein R. et al. (2013 a) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int 24: 227–235.
45. McClung M. Zanchetta J. Hoiseth A. Kendler D. Yuen C. Brown J. et al. (2013 b) Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis. J Clin Densitom 16: 250–256.
46. Mellstrom D. Sorensen O. Goemaere S. Roux C. Johnson T. Chines A. (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75: 462–468.
47. Ominsky M. Libanati C. Boyce R. Kostenuik P. Baron R. Wagman R. et al. (2013) Continuous modeling-based bone formation: a novel mechanism that could explain the sustained increases in hip bone mineral density (BMD) with denosumab treatment.J Bone Miner Res 28:(Suppl. 1): abstract #LB-MO30. Available at: http://www.asbmr.org/education/2013-abstracts (accessed 23 August 2014).
48. Ominsky M. Libanati C. Boyce R. Kostenuik P. Baron R. Wagman R. et al. (2014) Continuous modelling-based bone formation could explain sustained increases in hip bone mineral density with denosumab treatment. Presented at the European Calcified Tissue Society Conference 2014. Abstract #pp355. Available at: http://www.bone-abstracts.org/ba/0003/ba0003pp355.htm (accessed 5 July 2014).
49. Ominsky M. Stouch B. Schroeder J. Pyrah I. Stolina M. Smith S. et al. (2011) Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone 49: 162–173.
50. Oxlund H. Ejersted C. Andreassen T. Torring O. Nilsson M. (1993) Parathyroid hormone (1–34) and (1–84) stimulate cortical bone formation both from periosteum and endosteum. Calcif Tissue Int 53: 394–399.
51. Papapoulos S. Chapurlat R. Libanati C. Brandi M. Brown J. Czerwinski E. et al. (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27: 694–701.
52. Poole K. Treece G. Gee A. Brown J. McClung M. Wang A. et al. (2014) Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis. J Bone Miner Res 4 August (epub ahead of print).
53. Recker R. Bare S. Smith S. Varela A. Miller M. Morris S. et al. (2009) Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1–84. Bone 44: 113–119.
54. Recknor C. Czerwinski E. Bone H. Bonnick S. Binkley N. Palacios S. et al. (2013) Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol 121: 1291–1299.
55. Reid I. Miller P. Brown J. Kendler D. Fahrleitner-Pammer A. Valter I. et al. (2010) Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 25: 2256–2265.
56. Roux C. Hofbauer L. Ho P. Wark J. Zillikens M. Fahrleitner-Pammer A. et al. (2014) Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 58: 48–54.
57. Samelson E. Miller P. Christiansen C. Daizadeh N. Grazette L. Anthony M. et al. (2014) RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res 29: 450–457.
58. Seeman E. Delmas P. Hanley D. Sellmeyer D. Cheung A. Shane E. et al. (2010) Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 25: 1886–1894.
59. Simon J. Recknor C. Moffett A. Jr Adachi J. Franek E. Lewiecki E. et al. (2013) Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause 20: 130–137.
60. Simonet W. Lacey D. Dunstan C. Kelley M. Chang M. Luthy R. et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309–319.
61. Wasnich R. Miller P. (2000) Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85: 231–236.
62. Yasuda H. Shima N. Nakagawa N. Yamaguchi K. Kinosaki M. Mochizuki S. et al. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 3597–3602.
63. Yeni Y. Brown C. Wang Z. Norman T. (1997) The influence of bone morphology on fracture toughness of the human femur and tibia. Bone 21: 453–459.
64. Zebaze R. Libanati C. Austin M. Ghasem-Zadeh A. Hanley D. Zanchetta J. et al. (2014 a) Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone 59: 173–179.
65. Zebaze R. Libanati C. McClung M. Zanchetta J. Kendler D. Höiseth A. et al. (2014 b) Denosumab treatment in women with osteoporosis reduces hip cortical porosity. Presented at the European Calcified Tissue Society Conference 2014. Abstract #pp354. Available at: http://www.bone-abstracts.org/ba/0003/ba0003pp355.htm (accessed 28 August 2014).